Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors

Drug Metabolism and Disposition

Volumn 38, Issue 12, 2010, Pages 2195-2203

  Nath, Abhinav ^a   Zientek, Michael A ^b   Burke, Benjamin J ^b   Jiang, Ying ^b   Atkins, William M ^c  

^a YALE UNIVERSITY   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMIODARONE; AMITRIPTYLINE; ARTEMISININ; ASTEMIZOLE; ATENOLOL; BEPRIDIL; BUDESONIDE; CARBAMAZEPINE; CHLOROQUINE; CHLORPHENIRAMINE; CHLORTALIDONE; CIMETIDINE; CISAPRIDE; CLOTRIMAZOLE; CLOZAPINE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DANAZOL; DEXAMETHASONE; DIGOXIN; DILTIAZEM; DIPHENHYDRAMINE; DISULFIRAM; ERYTHROMYCIN; FELBAMATE; FLUCONAZOLE; FLURBIPROFEN; UNINDEXED DRUG;

ARTICLE; CHEMOSENSITIVITY; CLINICAL TRIAL; CORRELATIONAL STUDY; DRUG POTENCY; DRUG SPECIFICITY; ENTROPY; ENZYME INHIBITION; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; MALE; PARTIAL LEAST SQUARES REGRESSION; PRIORITY JOURNAL;

CYTOCHROME P-450 ENZYME SYSTEM; ENTROPY; ENZYME INHIBITORS; ISOENZYMES; LEAST-SQUARES ANALYSIS;

EID: 78649542235     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034645     Document Type: Article

References (28)

1. Abdi H (2003) Partial least squares (PLS) regression, in Encyclopedia for Research Methods for the Social Sciences (Lewis-Beck M, Bryman A, and Futing T eds), pp 792-795, Sage, Thousand Oaks, CA.
2. Arimoto R, Prasad MA, and Gifford EM (2005) Development of CYP3A4 inhibition models: comparisons of machine-learning techniques and molecular descriptors. J Biomol Screen 10:197-205. (Pubitemid 40617157)
3. Atkins WM (2004) Implications of the allosteric kinetics of cytochrome P450s. Drug Discov Today 9:478-484.
4. Coan KE and Shoichet BK (2008) Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J Am Chem Soc 130:9606-9612.
5. Coon MJ (2005) Cytochrome P450: nature's most versatile biological catalyst. Annu Rev Pharmacol Toxicol 45:1-25.
6. Durant JL, Leland BA, Henry DR, and Nourse JG (2002) Reoptimization of MDL keys for use in drug discovery. J Chem Inf Comput Sci 42:1273-1280.
7. Ghoreschi K, Laurence A, and O'Shea JJ (2009) Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 10:356-360.
8. Greenblatt DJ and von Moltke LL (2010) Clinical studies of drug-drug interactions: design and interpretation, in Enzyme- and Transporter-Based Drug-Drug Interactions (K.S. Pang, A.D. Rodrigues, and R.M. Peter, eds), pp 625-649, Springer, New York.
9. Jaynes ET (1957) Information theory and statistical mechanics. Phys Rev 106:620-630.
10. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, et al. (2009) Predicting new molecular targets for known drugs. Nature 462:175-181.
11. Maly DJ, Choong IC, and Ellman JA (2000) Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc Natl Acad Sci USA 97:2419-2424.
12. Merkwirth C, Mauser H, Schulz-Gasch T, Roche O, Stahl M, and Lengauer T (2004) Ensemble methods for classification in cheminformatics. J Chem Inf Comput Sci 44:1971-1978.
13. Nath A and Atkins WM (2008a) A quantitative index of substrate promiscuity. Biochemistry 47:157-166.
14. Nath A and Atkins W (2008b) Principal component analysis of CYP2C9 and CYP3A4 probe substrate/inhibitor panels. Drug Metab Dispos 36:2151-2155.
15. Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162.
16. Nivoix Y, Levêque D, Herbrecht R, Koffel JC, Beretz L, and Ubeaud-Sequier G (2008) The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 47:779-792.
17. Peters JU, Schnider P, Mattei P, and Kansy M (2009) Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 4:680-686.
18. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
19. Shah AR, Agarwal K, Baker ES, Singhal M, Mayampurath AM, Ibrahim YM, Kangas LJ, Monroe ME, Zhao R, Belov ME, et al. (2010) Machine learning based prediction for peptide drift times in ion mobility spectrometry. Bioinformatics 26:1601-1607.
20. Shannon CE (1948) A mathematical theory of communication. Bell System Technical Journal 27:379-423.
21. Shoichet BK (2006) Screening in a spirit haunted world. Drug Discov Today 11:607-615.
22. Smith D, Sadagopan N, Zientek M, Reddy A, and Cohen L (2007) Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. J Chromatogr B Analyt Technol Biomed Life Sci 850:455-463.
23. Stoner CL, Wester MR, and Burke BJ (2010) In silico approaches to predict DDIs, in Enzymeand Transporter-Based Drug-Drug Interactions (Pang KS, Rodrigues AD, and Peter RM eds), pp 151-168, Springer, New York.
24. Ustün B, Melssen WJ, and Buydens LM (2007) Visualisation and interpretation of support vector regression models. Anal Chim Acta 595:299-309.
25. Veith H, Southall N, Huang R, James T, Fayne D, Artemenko N, Shen M, Inglese J, Austin CP, Lloyd DG, et al. (2009) Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nat Biotechnol 27:1050-1055.
26. Wen B, Coe KJ, Rademacher P, Fitch WL, Monshouwer M, and Nelson SD (2008) Comparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase. Chem Res Toxicol 21:2393-2406.
27. Zientek M, Miller H, Smith D, Dunklee MB, Heinle L, Thurston A, Lee C, Hyland R, Fahmi O, and Burdette D (2008) Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J Pharmacol Toxicol Methods 58:206-214.
28. Zientek M, Stoner C, Ayscue R, Klug-McLeod J, Jiang Y, West M, Collins C, and Ekins S (2010) Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol 23:664-676.